101136439

Utolsó frissítés: 2024 április 30.

Projekt azonosító:
101136439
Projekt acronym:
VAX4ASF
Projekt címe:
Advancing vaccine development for African swine fever
Elnyert támogatás EUR:
109000 €
Konzorciumvezető:
Laboratorios HIPRA, Spain
Partnerek:
•    Agencia Estatal Consejo Superior de Investigaciones Científicas M.P., Spain
•    Ludwig-Maximilians Universität München, Germany
•    PIWET / National Veterinary Research Institute, Poland
•    International Livestock Research Institute, Kenya
•    Statens Veterinärmedi. Anstalt, Sweden
•    Sabiotec spin-off, Spain
•    In3diagnostic s.r.l., Italy
•    Stitching Wageningen Research, The Netherlands
•    PROPHYL Kft., Hungary
•    University of Life Sciences, Romania
•    National Organisation of Pork Producers, Spain
•    Spanish Inter-Profess. Agri-food organisation for White Pork, Spain
•    ZABALA Innovation Consulting s.a., Spain
•    Hungarian Univeristy of Agriculture and Life Sciences, Hungary
•    Kansas State University, USA
•    The Pirbright Institute, UK
A projekt tartalmának bemutatása:
The European project VAX4ASF —New Technologies for African Swine Fever (ASF)— begins with the aim of developing a next-generation vaccine against ASF virus, finding a means to eradicating the disease globally. Led by the biotechnological pharmaceutical company HIPRA and supported by the European Union under the Horizon Europe program, the goal of VAX4ASF is to provide a definitive, effective, and safe solution against the highly contagious, unpredictable, and complex ASF virus that affects pigs and wild boars, causing high mortality among the affected animals. The project aims to innovate based on previous vaccination approaches and strategies with the potential for success.
To address the challenges posed by an innovative vaccination approach, VAX4ASF brings together 17 partners from European Union countries, the United States and Kenya, in an international consortium.